merged_eli-lilly-zepbound-price.txt


<question_number>1</question_number>
<answer>offering FDA-approved medication with safety and quality oversight compared to less-regulated compounded drugs</answer>
<question_number>2</question_number>
<answer>by selling directly through LillyDirect, bypassing third-party telehealth platforms and undercutting their pricing</answer>
<question_number>3</question_number>
<answer>lack of safety, quality, and effectiveness oversight</answer>
<question_number>4</question_number>
<answer>regaining customers from compounding pharmacies despite potential self-cannibalization of pen sales</answer>
<question_number>5</question_number>
<answer>removal from the FDA's shortage list would eliminate compounding pharmacies' legal basis to produce tirzepatide</answer>
<question_number>6</question_number>
<answer>direct-to-consumer sales through LillyDirect remove third-party supply chain entities for transparent pricing</answer>
<question_number>7</question_number>
<answer>increased use of Zepbound vials by Medicare beneficiaries despite coverage restrictions and associated risks</answer>
<question_number>8</question_number>
<answer>positioning Zepbound vials as a safer alternative, highlighting compounded drugs' lack of FDA approval</answer>
<question_number>9</question_number>
<answer>listed as "in shortage" by the FDA</answer>
<question_number>10</question_number>
<answer>using lower pricing to compete directly with compounding pharmacies' cost advantage</answer>